| Autor: |
Gatwood KS; Vanderbilt University Medical Center, Nashville, TN, USA. katie.s.gatwood@vumc.org., Labopin M; EBMT Paris Study Office/CEREST-TC, Paris, France., Savani BN; Vanderbilt University Medical Center, Nashville, TN, USA., Finke J; University of Freiburg Department of Medicine-Hematology, Oncology, Freiburg, Germany., Socie G; Department of Hematology-BMT, Hospital St. Louis, Paris, France., Beelen D; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany., Yakoub-Agha I; Hôpital HURIEZ, UAM allo-CSH, CHRU, Lille, France., Chevallier P; Dept. D'Hématologie, CHU Nantes, Nantes, France., Ganser A; Department of Haematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str.1, Hannover, Germany., Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France., Milpied N; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France., Bruno L; Techniciens d'Etude Clinique suivi de patients greffes, Nouvel Hopital Civil, Strasbourg, France., Mailhol A; EBMT Paris Study Office/CEREST-TC, Paris, France., Mohty M; Department of Hematology, Hopital Saint Antoine, Paris, France., Nagler A; Department of Hematology, Hopital Saint Antoine, Paris, France.; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel. |
| Abstrakt: |
Allogeneic hematopoietic cell transplant (HCT) is a curative therapy for patients with secondary acute myeloid leukemia (sAML), though the impact of conditioning regimens on HCT outcomes for patients with antecedent lymphoid malignancy is largely unknown. This multicenter, retrospective registry study of the ALWP of the EBMT assessed HCT outcomes in this population. In all, 549 patients ≥18 years with sAML following an antecedent lymphoid malignancy treated with first allograft between 2000-2016 were included. Myeloablative (MAC) and reduced intensity conditioning (RIC) was given in 258 (47%) and 291 (53%), respectively. At 2 years, leukemia-free survival (LFS) was 31.7% (95% CI, 27.5-35.9), overall survival (OS) was 37.4% (95% CI, 33-41.8), nonrelapse mortality (NRM) was 28.9% (95% CI, 25-33), and GVHD-free, relapse-free survival (GRFS) was 22.8% (95% CI, 19-26.6). In multivariate analysis, patients receiving RIC regimens had lower risk of NRM (HR: 0.58, CI: 0.40-0.83, p = 0.003), and improved LFS (HR: 0.67, CI: 0.52-0.85, p = 0.001). Patients with prior autologous HCT had inferior LFS (HR: 1.30, CI: 1.01-1.67, p = 0.01). This study demonstrates that sAML patients following prior lymphoid malignancy treated with RIC regimens have a lower risk of NRM and improved LFS, OS, and GFRS. Other variables associated with inferior outcomes include older age, active disease, adverse cytogenetics, and prior auto-HCT. |
Full text from SpringerLink